https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / J. Virol. 2010 Jan;84(1):639-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / J. Virol. 2010 Jan;84(1):639-462010-01-01 00:00:002010-01-01 00:00:00The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Int J Hyperthermia 2010;26(2):108-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Int J Hyperthermia 2010;26(2):108-172010-01-01 00:00:002019-02-15 08:39:21Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Crit. Rev. Immunol. 2010;30(4):345-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Crit. Rev. Immunol. 2010;30(4):345-862010-01-01 00:00:002019-02-15 08:40:16Tumor antigen presentation by dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Hum. Immunol. 2010 Jan;71(1):67-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Hum. Immunol. 2010 Jan;71(1):67-732010-01-01 00:00:002019-02-15 08:44:09Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Methods Mol. Biol. 2010;595:149-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Methods Mol. Biol. 2010;595:149-632010-01-01 00:00:002019-02-15 08:44:11Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Immunotherapy 2010 Jan;2(1):57-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Immunotherapy 2010 Jan;2(1):57-682010-01-01 00:00:002019-02-15 08:45:16Personalized dendritic cell-based tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):139-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):139-572010-01-01 00:00:002019-02-15 08:46:45Dendritic cell vaccines for brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-109
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-1092010-01-01 00:00:002019-02-15 08:47:25Clinical applications of a peptide-based vaccine for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):195-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):195-92010-01-01 00:00:002019-02-15 08:59:37Monitoring immune responses after glioma vaccine immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-572010-01-01 00:00:002019-02-15 09:17:27Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments
